NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis $5.44 +0.04 (+0.74%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.34▼$5.9250-Day Range$3.12▼$5.5752-Week Range$1.63▼$8.83Volume1.44 million shsAverage Volume2.61 million shsMarket Capitalization$619.24 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Fate Therapeutics alerts: Email Address Fate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.21 Rating ScoreUpside/Downside24.1% Upside$6.75 Price TargetShort InterestBearish17.82% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.27Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.90) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.66 out of 5 starsMedical Sector271st out of 936 stocksBiological Products, Except Diagnostic Industry37th out of 154 stocks 3.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageFate Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fate Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.82% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 2.4 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($1.90) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Fate Therapeutics Stock (NASDAQ:FATE)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesJuly 25 at 4:26 PM | msn.comMy Nurse Was Terrified. I Knew Why I Was Dying—but I Couldn't SpeakJuly 25 at 4:26 PM | finance.yahoo.comAddex Therapeutics Ltd (APE1.F)July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 25 at 11:25 AM | nz.finance.yahoo.comFate Therapeutics Inc (F6T.MU)July 21, 2024 | fool.comBillionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?July 2, 2024 | globenewswire.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 13, 2024 | prnewswire.comFATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the FirmJune 4, 2024 | globenewswire.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 29, 2024 | globenewswire.comFate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceMay 28, 2024 | finance.yahoo.comNew Memoir "Echoes of Fate: From Birth to the Last Heartbeats" Captures the Essence of Human Existence and LegacyMay 16, 2024 | markets.businessinsider.comFate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy RatingMay 14, 2024 | markets.businessinsider.comHold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline FocusMay 13, 2024 | seekingalpha.comFate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comFate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineMay 10, 2024 | markets.businessinsider.comFate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical ResultsMay 10, 2024 | finance.yahoo.comFate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...See More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees181Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+24.1%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-2,933.79% Pretax Margin-2,933.79% Return on Equity-46.49% Return on Assets-34.48% Debt Debt-to-Equity RatioN/A Current Ratio8.69 Quick Ratio8.69 Sales & Book Value Annual Sales$63.53 million Price / Sales9.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book1.45Miscellaneous Outstanding Shares113,830,000Free Float108,140,000Market Cap$619.24 million OptionableOptionable Beta1.90 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 54)Founder, CEO, President & Director Comp: $920.4kMr. Edward J. Dulac III (Age 48)Chief Financial Officer Comp: $612.5kMs. Cindy R. Tahl J.D. (Age 51)General Counsel, Corporate Secretary & Compliance Officer Comp: $612.5kDr. Bahram Valamehr Ph.D. (Age 47)Chief Research & Development Officer Comp: $644.5kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityDr. Barbara HickingbottomSenior VP of Clinical DevelopmentMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPbluebird bioNASDAQ:BLUECellectisNASDAQ:CLLSAtara BiotherapeuticsNASDAQ:ATRACelyad OncologyNASDAQ:CYADView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 72,139 shares on 7/26/2024Ownership: 0.329%Assenagon Asset Management S.A.Bought 26,399 shares on 7/18/2024Ownership: 2.262%Artal Group S.A.Bought 360,311 shares on 5/17/2024Ownership: 0.317%Bayesian Capital Management LPBought 20,164 shares on 5/16/2024Ownership: 0.035%California State Teachers Retirement SystemSold 5,430 shares on 5/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions FATE Stock Analysis - Frequently Asked Questions How have FATE shares performed this year? Fate Therapeutics' stock was trading at $3.74 at the start of the year. Since then, FATE shares have increased by 45.5% and is now trading at $5.44. View the best growth stocks for 2024 here. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.47). The biopharmaceutical company had revenue of $1.93 million for the quarter, compared to analysts' expectations of $0.80 million. Fate Therapeutics had a negative net margin of 2,933.79% and a negative trailing twelve-month return on equity of 46.49%. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (2.26%) and Bank of New York Mellon Corp (0.33%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, John Mendlein, Bahram Valamehr, Cindy Tahl, Yu-Waye Chu, Mark Plavsic, Edward J Dulac III, Brian T Powl and Yuan Xu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD) and Exelixis (EXEL). This page (NASDAQ:FATE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
